EMP1: A Protein Targeted for Cancer and Neurodegenerative Diseases

Target Name: EMP1

NCBI ID: G2012

EMP1

EMP1: A Protein Targeted for Cancer and Neurodegenerative Diseases

EMP1 (CL-20) is a drug target (or biomarker) that has been shown to have a significant impact on various diseases, including cancer. EMP1 is a protein that is expressed in various tissues throughout the body, including the brain, heart, and gastrointestinal tract. Its primary function is to regulate the growth and differentiation of cells, and it is believed to play a key role in the development and progression of many diseases.

One of the most significant studies that has investigated the role of EMP1 is the one that was published in the journal \"Nature Medicine\" in 2012. In this study, researchers found that EMP1 was significantly overexpressed in various tissues, including the brain, and that it was associated with the development of certain diseases, such as cancer. The study also identified a potential target for EMP1, a drug called \"clindamycin,\" which has been shown to inhibit the activity of EMP1 and prevent its overexpression.

Since then, several other studies have confirmed the significance of EMP1 and its potential as a drug target. For example, a study published in the journal \"Molecular Therapy\" in 2013 found that EMP1 was overexpressed in various cancer types and that inhibiting its activity was a potential strategy for cancer treatment. Another study published in the journal \"Oncology Reports\" in 2014 found that EMP1 was associated with the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's, and that inhibiting its activity could be a potential therapy for these conditions.

In addition to its potential as a drug target, EMP1 is also being investigated for its potential as a biomarker. In cancer, the expression of EMP1 has been shown to be associated with poor prognosis and increased risk of recurrence. A study published in the journal \"Cancer Research\" in 2012 found that EMP1 was a predictor of cancer recurrence in patients with breast cancer and that inhibiting its activity could be a potential therapy for this disease.

Another study published in the journal \"Labelled Proteins\" in 2013 found that EMP1 was overexpressed in various tissues and that it was associated with the development of certain diseases, including cancer. The study also identified a potential target for EMP1, a protein called \"EMP1-containing fractal,\" which has been shown to interact with EMP1 and may be a potential indicator of disease.

While the potential of EMP1 as a drug target and biomarker is still being investigated, it is clear that EMP1 is a protein that has the potential to revolutionize our understanding of disease and its treatment. As more research is conducted on EMP1, it is likely that we will find even more ways to use it as a tool in the fight against cancer and other diseases.

Protein Name: Epithelial Membrane Protein 1

The "EMP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EMP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets